计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| P413567-5mg |
5mg |
现货 ![]() |
| |
| P413567-25mg |
25mg |
现货 ![]() |
| |
| P413567-50mg |
50mg |
现货 ![]() |
| |
| P413567-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | BDBM50133595 | SCHEMBL14936135 | ICYNYWFGIDGBRD-UHFFFAOYSA-N | 2-[6-(5-chloro-2-methoxyphenyl)-4-oxo-2-sulfanylidenepyrimidin-1-yl]acetamide | GTPL10053 | PF 06282999 | PF06282999 | PF-06282999 | BCP20203 | A902781 | compound 8 [PMID: 26509551] | YO3O4Q2N |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | PF-06282999 |
| 生化机理 | PF-06282999 是一种口服生物可利用、不可逆的髓过氧化物酶灭活剂,目前正处于临床试验阶段,可能用于治疗心血管疾病。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 髓过氧化物酶抑制剂 |
| 产品介绍 |
PF-06282999 是一种有效的,选择性的髓过氧物酶 (myeloperoxidase) 抑制剂,用于心血管疾病的研究。 Information PF-06282999 PF-06282999 is an orally bioavailable, irreversible inactivator of myeloperoxidase enzyme and is currently in clinical trials for the potential treatment of cardiovascular diseases. Targets MPO (LPS-stimulated human whole blood) 1.9 μM Product Describtion: PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases. |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 488202262 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 2-[6-(5-chloro-2-methoxyphenyl)-4-oxo-2-sulfanylidenepyrimidin-1-yl]acetamide |
| INCHI | 1S/C13H12ClN3O3S/c1-20-10-3-2-7(14)4-8(10)9-5-12(19)16-13(21)17(9)6-11(15)18/h2-5H,6H2,1H3,(H2,15,18)(H,16,19,21) |
| InChi Key | ICYNYWFGIDGBRD-UHFFFAOYSA-N |
| Smiles | COC1=C(C=C(C=C1)Cl)C2=CC(=O)NC(=S)N2CC(=O)N |
| Isomeric SMILES | COC1=C(C=C(C=C1)Cl)C2=CC(=O)NC(=S)N2CC(=O)N |
| PubChem CID | 71571306 |
| 分子量 | 325.77 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 65 mg/mL (199.52 mM); Water: Insoluble; Ethanol: Insoluble; |
|---|---|
| 分子量 | 325.770 g/mol |
| XLogP3 | 1.000 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 4 |
| 精确质量Exact Mass | 325.029 Da |
| 单同位素质量Monoisotopic Mass | 325.029 Da |
| 拓扑极表面积Topological Polar Surface Area | 117.000 Ų |
| 重原子数Heavy Atom Count | 21 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 497.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| RIDADR | NONHforallmodesoftransport |
|---|
| 1. Ruggeri RB, Buckbinder L, Bagley SW, Carpino PA, Conn EL, Dowling MS, Fernando DP, Jiao W, Kung DW, Orr ST et al.. (2015) Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases.. J Med Chem, 58 (21): (8513-28). [PMID:26509551] |
| 2. Dong JQ, Varma MV, Wolford A, Ryder T, Di L, Feng B, Terra SG, Sagawa K, Kalgutkar AS. (2016) Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans.. Drug Metab Dispos, 44 (2): (209-19). [PMID:26608081] |